

PHARMACEUTICAL 2019

NANOVIRICIDES INC. Rank 58 of 363







RealRate

PHARMACEUTICAL 2019

NANOVIRICIDES INC. Rank 58 of 363

The relative strengths and weaknesses of NANOVIRICIDES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NANOVIRICIDES INC. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 132% points. The greatest weakness of NANOVIRICIDES INC. is the variable Other Revenues, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 225%, being 188% points above the market average of 37%.

| Input Variable                              | Value in<br>1000 USD |
|---|----------------------|
| Assets, Current                             | 7,322                |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 375                  |
| Liabilities, Current                        | 882                  |
| Liabilities, Non-Current                    | 0                    |
| Other Assets                                | 8.2                  |
| Other Compr. Net Income                     | 0                    |
| Other Expenses                              | 0                    |
| Other Liabilities                           | 0                    |
| Other Net Income                            | 762                  |
| Other Revenues                              | 0                    |
| Property and Equipment                      | 10,841               |
| Research and Development                    | 4,827                |
| Selling, General and Administrative Expense | 4,498                |

| Output Variable          | Value in<br>1000 USD |
|--------------------------|----------------------|
| Assets                   | 18,546               |
| Liabilities              | 882                  |
| Expenses                 | 9,325                |
| Revenues                 | 0                    |
| Stockholders Equity      | 17,664               |
| Net Income               | -8,563               |
| Comprehensive Net Income | -8,563               |
| Economic Capital Ratio   | 225%                 |

